Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

Sponsor
Hunan Province Tumor Hospital
Study ID
NCT05295212
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Pemetrexed (500mg/m2)/Paclitaxel (260mg/m2) Carboplatin (AUC=4-5) Atezolizumab(1200mg) ivgtt, every 21 days Range from 4 cycles

Study Details

This study aimed to evaluate the efficacy, safety, tolerability, feasibility of surgery, and incidence of preoperative and postoperative complications of atezolizumab in combination with platinum-based chemotherapy with resectable stage II-IIIB non-small cell lung cancer.

Key Dates

Start date
Feb 1, 2023
Status verified
Sep 2024
Primary completion
Dec 1, 2024
Completion
Jul 1, 2025

Study Design

Enrollment
120 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • No Intervention: Cohort A
    MRD revealed negative
  • Experimental: Cohort B
    MRD revealed positive

Primary Outcome Measure

MPR Rate [ Time Frame: 1.5 year ]

Central Contacts

Related Studies